China Universal Asset Management Co. Ltd. Has $1.01 Million Stock Position in Kymera Therapeutics, Inc. $KYMR

China Universal Asset Management Co. Ltd. raised its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 77.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,079 shares of the company’s stock after acquiring an additional 10,052 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Kymera Therapeutics were worth $1,007,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Siren L.L.C. grew its position in Kymera Therapeutics by 9.1% in the first quarter. Siren L.L.C. now owns 3,240,313 shares of the company’s stock valued at $88,687,000 after purchasing an additional 270,580 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of Kymera Therapeutics by 26.3% during the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock worth $4,689,000 after buying an additional 22,392 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Kymera Therapeutics by 9.0% during the 1st quarter. Rhumbline Advisers now owns 69,928 shares of the company’s stock worth $1,914,000 after buying an additional 5,771 shares during the last quarter. Atika Capital Management LLC bought a new position in shares of Kymera Therapeutics in the 2nd quarter valued at about $6,398,000. Finally, Farther Finance Advisors LLC increased its position in shares of Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after acquiring an additional 540 shares during the last quarter.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $89.68 on Monday. The business has a fifty day simple moving average of $64.77 and a two-hundred day simple moving average of $52.18. Kymera Therapeutics, Inc. has a 1 year low of $19.44 and a 1 year high of $103.00. The company has a market capitalization of $6.45 billion, a price-to-earnings ratio of -24.98 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.19). The company had revenue of $2.76 million during the quarter, compared to analyst estimates of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. As a group, equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Bros. Advisors Lp Baker purchased 2,005,813 shares of the stock in a transaction on Thursday, December 11th. The shares were purchased at an average cost of $86.00 per share, with a total value of $172,499,918.00. Following the acquisition, the director directly owned 7,955,916 shares in the company, valued at $684,208,776. The trade was a 33.71% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jared Gollob sold 59,576 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $61.42, for a total value of $3,659,157.92. Following the sale, the insider owned 109,992 shares of the company’s stock, valued at approximately $6,755,708.64. This represents a 35.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 597,805 shares of company stock worth $46,839,199 in the last 90 days. Corporate insiders own 16.01% of the company’s stock.

Analyst Ratings Changes

KYMR has been the subject of several recent research reports. JPMorgan Chase & Co. increased their price target on Kymera Therapeutics from $70.00 to $125.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Truist Financial upped their price objective on Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Wednesday, October 8th. B. Riley upped their price target on shares of Kymera Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, October 24th. Finally, Stephens increased their price target on shares of Kymera Therapeutics from $65.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $112.80.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.